GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioArctic AB (OTCPK:BRCTF) » Definitions » Scaled Net Operating Assets

BRCTF (BioArctic AB) Scaled Net Operating Assets : 0.44 (As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is BioArctic AB Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

BioArctic AB's operating assets for the quarter that ended in Jun. 2024 was $61.25 Mil. BioArctic AB's operating liabilities for the quarter that ended in Jun. 2024 was $13.63 Mil. BioArctic AB's Total Assets for the quarter that ended in Mar. 2024 was $109.14 Mil. Therefore, BioArctic AB's scaled net operating assets (SNOA) for the quarter that ended in Jun. 2024 was 0.44.


BioArctic AB Scaled Net Operating Assets Historical Data

The historical data trend for BioArctic AB's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioArctic AB Scaled Net Operating Assets Chart

BioArctic AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only -0.08 -0.07 -0.04 -0.01 -0.07

BioArctic AB Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.04 0.39 -0.05 0.42 0.44

Competitive Comparison of BioArctic AB's Scaled Net Operating Assets

For the Biotechnology subindustry, BioArctic AB's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioArctic AB's Scaled Net Operating Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioArctic AB's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where BioArctic AB's Scaled Net Operating Assets falls into.



BioArctic AB Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

BioArctic AB's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2023 )
=(Operating Assets (A: Dec. 2023 )-Operating Liabilities (A: Dec. 2023 ))/Total Assets (A: Dec. 2022 )
=(7.264-13.114)/82.704
=-0.07

where

Operating Assets(A: Dec. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=115.629 - 108.365
=7.264

Operating Liabilities(A: Dec. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=13.6 - 0.21 - 0.276
=13.114

BioArctic AB's Scaled Net Operating Assets (SNOA) for the quarter that ended in Jun. 2024 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Jun. 2024 )
=(Operating Assets (Q: Jun. 2024 )-Operating Liabilities (Q: Jun. 2024 ))/Total Assets (Q: Mar. 2024 )
=(61.247-13.627)/109.144
=0.44

where

Operating Assets(Q: Jun. 2024 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=107.941 - 46.694
=61.247

Operating Liabilities(Q: Jun. 2024 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=19.32 - 4.458 - 1.235
=13.627

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioArctic AB Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of BioArctic AB's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


BioArctic AB Business Description

Industry
Traded in Other Exchanges
Address
Warfvinges vag 35, Stockholm, SWE, SE-112 51
BioArctic AB is a research-based biopharmaceutical company focusing on disease-modifying treatments and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, and ALS. In addition, the group is also focused on the development of a treatment with a combination of a biodegradable medical device and a drug substance for complete spinal cord injury. Geographically, it derives a majority of its revenue from Asia.

BioArctic AB Headlines

From GuruFocus

Q2 2021 BioArctic AB Earnings Call Transcript

By GuruFocus Research 02-13-2024

Q2 2020 BioArctic AB Earnings Call Transcript

By GuruFocus Research 02-13-2024

Q1 2019 BioArctic AB Earnings Call Transcript

By GuruFocus Research 02-13-2024

Q4 2021 BioArctic AB Earnings Call Transcript

By GuruFocus Research 02-13-2024

Q1 2022 BioArctic AB Earnings Call Transcript

By GuruFocus Research 02-13-2024

BioArctic winner of the Allbright Award 2020

By PRNewswire PRNewswire 10-15-2020

Full Year 2018 BioArctic AB Earnings Call Transcript

By GuruFocus Research 02-13-2024

Q2 2019 BioArctic AB Earnings Call Transcript

By GuruFocus Research 02-13-2024